

Message

---

**From:** Charlotte Sanson [charlotte.sanson@bayer.com]  
**Sent:** 4/25/2017 4:58:03 PM  
**To:** Keigwin, Richard [Keigwin.Richard@epa.gov]  
**Subject:** RE: Brief visit

Hi Rick,

Thinking a bit more about a proposed visit, we'd like to have a discussion on the status of isoxaflutole (Bayer's #1 registration priority for this year) and path forward. The current PRIA decision date is Sept. 30<sup>th</sup>. Suggest including Marietta Echeverria and Mike Goodis, if available. We can also be flexible to meet on either May 9<sup>th</sup> or 10<sup>th</sup>, depending on availability for is a 30 minute time slot.

Many thanks.

Freundliche Grüße / Best regards,

Charlotte Sanson  
VP, Regulatory Affairs & Compliance, Crop Science

Bayer US LLC  
2 T.W. Alexander Drive  
Research Triangle Park  
Tel: +1 919 549 2824  
Mobile: +1 919 215 4340  
Fax: +1 919 549 2524  
E-mail: [charlotte.sanson@bayer.com](mailto:charlotte.sanson@bayer.com)  
Web: <http://www.bayercropscience.com>

---

**From:** Charlotte Sanson  
**Sent:** Tuesday, April 25, 2017 9:57 AM  
**To:** 'Keigwin, Richard'  
**Subject:** Brief visit

Hi Rick,

I plan to be in Crystal City Wednesday, May 10<sup>th</sup>. Do you happen to be available for a brief visit that day? I can be flexible with the time. Bob Graney, head of North America Regulatory Science (my boss) would like to join, as he has not yet had the opportunity to meet you.

Thanks.

Freundliche Grüße / Best regards,

Charlotte Sanson  
VP, Regulatory Affairs & Compliance, Crop Science

Bayer US LLC  
2 T.W. Alexander Drive  
Research Triangle Park  
Tel: +1 919 549 2824  
Mobile: +1 919 215 4340

Fax: +1 919 549 2524  
E-mail: [charlotte.sanson@bayer.com](mailto:charlotte.sanson@bayer.com)  
Web: <http://www.bayercropscience.com>

---

*The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender. Thank you.*

---